Clinical Trial Update: Stroke Prevention in Sickle Cell Anemia (STOP 2) [Phase 3]

View source ↗

Summary

A Phase 3 trial (STOP 2) evaluating stroke prevention in sickle cell disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease
• Stroke

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Blood Disease, Cerebrovascular Accident | Phase 3 | Status: COMPLETED